STRO-001 Gets Orphan Drug Designation for Mutiple Myeloma

STRO-001 is a potential first-in-class antibody drug conjugate (ADC) targeting CD74
STRO-001 is a potential first-in-class antibody drug conjugate (ADC) targeting CD74

Sutro Biopharma announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation for STRO-001 for the treatment of multiple myeloma

STRO-001 targets CD74, which is a protein highly expressed in B-cell malignancies like multiple myeloma. This potential first-in-class antibody drug conjugate (ADC) was developed with the Company's proprietary cell-free protein synthesis and site-specific conjugation platform called XpressCF+. The technology allows for the manufacturing of a highly optimized single molecular species within the product instead of the usual mixture of imprecisely conjugated antibodies that make up an ADC product designed by conventional cell-based platforms. 

STRO-001 is being evaluated in a Phase 1 trial that includes separate dose escalation cohorts for multiple myeloma and B-cell lymphoma. 

Related Articles

For more information visit Sutrobio.com.